Novo Nordisk A/S (0QIU.IL)

858.65 -34.40 (-3.85%) At close: 06:45PM BST

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 59,337

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lars Fruergaard Jorgensen	Pres, CEO & Member of Management Board	32.3M	N/A	1966
Mr. Karsten Munk Knudsen	Exec. VP, CFO & Member of the Management Board	12.8M	N/A	1971
Mr. Henrik Ehlers Wulff	Exec. VP of Product Supply, Quality & IT and Member of the Management Board	12.9M	N/A	1970
Ms. Camilla Sylvest	Exec. VP of Commercial Strategy & Corp. Affairs and Member of the Management Board	12.6M	N/A	1972
Dr. Martin Holst Lange	Exec. VP of Devel. & Member of the Management Board	12.2M	N/A	1970
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Devel., Chief Scientific Officer & Member of the Management Board	12.2M	N/A	1966
Mr. Maziar Mike Doustdar	Exec. VP of International Operations & Member of the Management Board	N/A	N/A	1970
Mr. Douglas J. Langa	Exec. VP of North America Operations & Member of Management Board	N/A	N/A	1966
Mr. Ludovic Helfgott	Exec. VP, Head of Rare Disease & Member of Management Board	N/A	N/A	1974
Ms. Tania Sabroe	Exec. VP of Global People & Organisation and Member of Management Board	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 1 October 2023 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.